patented technology to grow and expand adult Stem Cells
Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

AGORACOM News Flash

AGORACOM WIRE - WEDNESDAY MAY 30TH, 2012

GOLDEN HOPE MINES (TSXV:GNH) Confirms High Grade Intersection of 64.1 g/t Au (Gold) over 1m Read More 

  • The screen metallic analysis returned 82 g/t Au for an average grade of 93.5 g/t Au.
  • Two additional fire assays on the original pulp done prior to the screen metallic analyses returned 0.22 g/t Au and 0.12 g/t Au for an average fire assay grade of 0.41 g/t Au. The weighted average of all the fire assays and screen metallic assays from this 1-metre section in hole BD2011-184 is 64.1 g/t Au.

Sonomax® eers™ Custom Earbuds Announces Sponsorship of MUTEK 2012

CONTINENTAL ENERGY  Geothermal Energy Project Receives US$ 11.5 Million Grant Read More * Client

AGORACOM Launches Graphite Stocks Blog

Top Stories

  • FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc. Read More   |   *SPONSOR

  • LOMIKO METALS (TSXV:LMK) Paul Gill Discusses Exploration Initiative with James West of Midas Letter Read More   |   *SPONSOR
  • GRAPHITE DEMAND Seen Surging from Fuel Cells, Nuclear Reactors, Graphene Read More

 

 

Message: NEWS: Pluristem Therapeutics Will Chair a Panel Presentation on Placenta-Derived

Generic_profile
Rank: [?]
Treasurer
Points: [?]
13873
Rating: [?]
Votes: 71 Score: 2.4
  • Currently 2.5/5 Stars.
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

NEWS: Pluristem Therapeutics Will Chair a Panel Presentation on Placenta-Derived

posted on Oct 21, 09 08:16AM

Pluristem Therapeutics Will Chair a Panel Presentation on Placenta-Derived Adult Stem Cells at the World Conference on Regenerative Medicine


  • Press Release
  • Source: Pluristem Therapeutics Inc.
  • On 9:00 am EDT, Tuesday October 20, 2009

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.

Contact:

Pluristem Therapeutics Inc.
William Prather RPh, MD
Sr. VP Corporate Development
+1-303-883-4954
William.PratherMD@pluristem.com
or
Russo Partners
Andreas Marathovouniotis
+1-212-845-4235
andreas.marathis@russopartnersllc.com

New Message

Please login to post a reply

AGORACOM Quick Tips

AGORACOM 100 - The Top 100 Small Caps ... Find Your Next Investment
Watch
Today's Show
in 00:00:000

President's D.D.

4-17-12, Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial for the treatment of peripheral artery disease (PAD). read more

Stock Quote

Hub Leaders